# CMTM7

## Overview
CMTM7, or CKLF-like MARVEL transmembrane domain containing 7, is a gene that encodes a transmembrane protein involved in various cellular processes, including autophagy and endosomal trafficking. The protein, characterized by its MARVEL domain, is a tetra-spanning membrane protein that plays a crucial role in membrane apposition events. CMTM7 is integral to the ATG14L-Beclin1-VPS34 complex, enhancing autophagic flux and promoting the maturation of autophagosomes. It also regulates epidermal growth factor receptor (EGFR) signaling by facilitating Rab5 activation, which is essential for early endosome fusion and EGFR trafficking. CMTM7's interactions with proteins such as CTNNA1 and Rab5 highlight its role in tumor suppression and cellular signaling pathways. Notably, CMTM7 is downregulated in breast cancer, where it acts as a tumor suppressor by inhibiting the Wnt/β-catenin signaling pathway, making it a potential therapeutic target (Lu2021Breast; Liu2021CMTM7; Chen2023CMTM7).

## Structure
CMTM7 is a transmembrane protein that belongs to the CKLF-like MARVEL transmembrane domain-containing family, characterized by the presence of MARVEL domains. These domains are involved in membrane apposition events and contribute to the protein's structural and functional roles (Liu2021CMTM7; Miyazaki2012Identification). CMTM7 is a tetra-spanning membrane protein, indicating it has multiple transmembrane helices, which are typical features of its secondary structure (Miyazaki2012Identification).

The C-terminal region of CMTM7 is crucial for its membrane localization and function, as it is necessary for the association with surface IgM (sIgM) and the recruitment of BLNK, an adaptor protein. This region's importance is highlighted by the failure of C-terminal truncated mutants to localize to the membrane or associate with sIgM (Miyazaki2012Identification).

CMTM7 also interacts with various proteins involved in autophagy, such as Beclin1 and Rab5, enhancing autophagic flux and playing a role in tumor suppression (Liu2021CMTM7). However, specific details on the primary, tertiary, or quaternary structure of CMTM7 are not provided in the available context.

## Function
CMTM7 is a protein involved in several critical cellular processes, particularly in regulating autophagy and endosomal trafficking. In healthy human cells, CMTM7 is a component of the ATG14L-Beclin1-VPS34 complex, which is essential for autophagy, a process that degrades and recycles cellular components. CMTM7 enhances autophagic flux by interacting with Rab5, a small GTPase involved in endocytic trafficking, promoting the formation and maturation of autophagosomes and their fusion with lysosomes (Liu2021CMTM7).

CMTM7 also plays a role in the regulation of epidermal growth factor receptor (EGFR) signaling. It promotes EGFR internalization and degradation by facilitating Rab5 activation, which is crucial for early endosome fusion and proper EGFR trafficking. This function helps maintain normal EGFR signaling, preventing aberrant oncogenic signaling pathways (Liu2015CMTM7).

CMTM7 is localized to early endosomes, where it co-localizes with Rab5 and EEA1, indicating its involvement in early endosome fusion and enlargement. This localization is critical for the regulation of EGFR degradation and the spatial and temporal distribution of EGFR in early endosomes (Liu2015CMTM7).

## Clinical Significance
CMTM7 is significantly downregulated in breast cancer tissues and cell lines compared to normal breast tissues, and this downregulation is associated with poor prognosis in breast cancer patients. Higher expression levels of CMTM7 correlate with improved overall survival, recurrence-free survival, and distant metastasis-free survival (Chen2023CMTM7). The gene's promoter region is often hypermethylated in breast cancer, leading to reduced expression, and treatment with a DNA methyltransferase inhibitor can increase CMTM7 expression, suggesting a regulatory role of methylation in its expression (Chen2023CMTM7).

CMTM7 inhibits breast cancer progression by regulating the Wnt/β-catenin signaling pathway. It interacts with CTNNA1, inhibiting the nuclear localization of β-catenin, which suppresses cell proliferation, invasion, and migration in breast cancer cells (Chen2023CMTM7). CMTM7 is also a target of miR-182-5p, a microRNA that negatively regulates its expression and promotes tumor progression (Lu2021Breast). The downregulation of CMTM7 by miR-182-5p activates the EGFR/AKT signaling pathway, contributing to tumorigenesis and metastasis (Lu2021Breast). These findings suggest that CMTM7 plays a critical role in breast cancer progression and could serve as a potential therapeutic target.

## Interactions
CMTM7 interacts with several proteins, playing a significant role in cellular processes such as autophagy and cancer progression. It is known to interact with CTNNA1 (Catenin Alpha 1), forming a complex that includes CTNNB1 (β-catenin) at the cell membrane. This interaction is crucial for inhibiting Wnt/β-catenin signaling by reducing the nuclear localization of CTNNB1, thereby acting as a tumor suppressor in breast cancer (Chen2023CMTM7).

CMTM7 also enhances autophagy by interacting with the ATG14L-Beclin1-VPS34 complex. It co-localizes with Beclin1, VPS34, and ATG14L, but not with ULK1, UVRAG, or LC3B, indicating a specific association with this complex. This interaction promotes autophagosome biogenesis and increases the activity of the VPS34 complex, enhancing the production of phosphatidylinositol 3-phosphate (PI(3)P) and recruiting autophagy effectors like WIPI-1 (Liu2021CMTM7).

CMTM7 also interacts with Rab5, a GTPase involved in vesicle trafficking, enhancing its association with the ATG14L-Beclin1-VPS34 complex. This interaction is important for autophagy regulation and tumor suppression, as CMTM7 acts as an activator of Rab5, influencing early endosome fusion and EGFR internalization (Liu2021CMTM7; Liu2015CMTM7).


## References


[1. (Lu2021Breast) Chong Lu, Yu Zhao, Jing Wang, Wei Shi, Fang Dong, Yue Xin, Xiangwang Zhao, and Chunping Liu. Breast cancer cell-derived extracellular vesicles transfer mir-182-5p and promote breast carcinogenesis via the cmtm7/egfr/akt axis. Molecular Medicine, July 2021. URL: http://dx.doi.org/10.1186/s10020-021-00338-8, doi:10.1186/s10020-021-00338-8. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s10020-021-00338-8)

[2. (Chen2023CMTM7) Zhao-Hui Chen, Yao Tian, Guang-Lei Zhou, Hao-Ran Yue, Xue-Jie Zhou, Hai-Yan Ma, Jie Ge, Xin Wang, Xu-Chen Cao, and Yue Yu. Cmtm7 inhibits breast cancer progression by regulating wnt/β-catenin signaling. Breast Cancer Research, February 2023. URL: http://dx.doi.org/10.1186/s13058-023-01620-9, doi:10.1186/s13058-023-01620-9. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/s13058-023-01620-9)

[3. (Liu2021CMTM7) Baocai Liu, Yinliang Lu, Tingting Zhang, Xinyue Yu, Qian Wang, Yunbo Chi, Shunzi Jin, and Guanghui Cheng. Cmtm7 as a novel molecule of atg14l-beclin1-vps34 complex enhances autophagy by rab5 to regulate tumorigenicity. Cell Communication and Signaling, July 2021. URL: http://dx.doi.org/10.1186/s12964-021-00720-3, doi:10.1186/s12964-021-00720-3. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-021-00720-3)

[4. (Miyazaki2012Identification) Atsuko Miyazaki, Satomi Yogosawa, Akikazu Murakami, and Daisuke Kitamura. Identification of cmtm7 as a transmembrane linker of blnk and the b-cell receptor. PLoS ONE, 7(2):e31829, February 2012. URL: http://dx.doi.org/10.1371/journal.pone.0031829, doi:10.1371/journal.pone.0031829. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0031829)

[5. (Liu2015CMTM7) Baocai Liu, Yu Su, Ting Li, Wanqiong Yuan, Xiaoning Mo, Henan Li, Qihua He, Dalong Ma, and Wenling Han. Cmtm7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and egfr-akt signaling by reducing rab5 activation. Oncotarget, 6(38):41092–41107, October 2015. URL: http://dx.doi.org/10.18632/oncotarget.5732, doi:10.18632/oncotarget.5732. This article has 33 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.5732)